acalabrutinib + omeprazole

acalabrutinib + omeprazole is not an approved or marketed fixed-dose combination product but rather the concurrent use of two independent drugs: acalabrutinib, a bruton tyrosine kinase (BTK) inhibitor primarily used for B-cell malignancies, and omeprazole, a proton pump inhibitor used to reduce gastric acid secretion. This combination is clinically important because omeprazole (and other proton pump inhibitors) significantly reduces the absorption of acalabrutinib when administered as a capsule by increasing gastric pH, which decreases acalabrutinib solubility and bioavailability. Co-administration reduces acalabrutinib's area under the curve (AUC) by approximately 43%, potentially lowering its therapeutic efficacy.

Brand names

Calquence (acalabrutinib)Prilosec (omeprazole)

Other names

acalabrutinibomeprazole